Pricing Log in Create free account
Saturday 17 October 2026 Export GOVX’s income statement to Excel — free account

GeoVax Labs Inc.

GOVX Healthcare Biotechnology

GeoVax Labs Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 million, down 37.1% from fiscal 2024. In the quarter to June 2026, revenue grew 183.4%, EPS grew 88.9% and free cash flow grew 15.8%, each against the same quarter a year earlier.

0.23 0.03 −11.54%
Market cap
$2.6M
P/E
0.0×
Fwd P/E
−0.2×
Dividend yield
—
F-score
n/a
Altman Z
−42.55
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 2.61
Revenue 6.14
Net Income (20.43)
Free Cash Flow (18.37)
Net Debt (3.14)
Current Ratio 1.54 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.19) (negative: loss-making)
P/S ratio 0.17
P/B ratio 0.60
Past 5Y EPS Growth —
This Y EPS Growth 77.05% (at or above 15%: strong)
Next Y EPS Growth 48.64% (at or above 15%: strong)
Next Y revenue growth (67.34%) (below 0%: weak)
Next 5Y EPS Growth 49.07% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.3×, against a ten-year median of 1.1×; over the ten years it ranged from −55.8× in 2022 to 68,586,623,689× in 2016.
P/S against its own 10 years 0.04%
10-year low 10-year high
P/B against its own 10 years 16.56%
10-year low 10-year high
EV/FCF against its own 10 years 12.80%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 6 6 3 3
Receivables — 1 — —
Inventory — — — —
Other — — — —
8 8 5 4
2023 2024 2025 Q'26
Payables 3 2 1 2
ST’ Debt — — — —
Other — — — —
4 3 2 3

Compound Annual Growth %

10y 5y 3y
Sales 10.92% 16.18% 86.21%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 12.25% (16.76%) (47.61%)

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 2 1 — — 2
’24 — 0 3 1 4
’22 0 — — — 0
’21 0 0 0 0 0
’20 1 0 0 0 2
’19 0 0 0 0 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (4) — — —
’25 (6) (4) (6) (5) (21)
’24 (6) (2) (9) (8) (25)
’23 (4) (6) (5) (10) (25)
’22 (4) (4) (4) (7) (19)
’21 (2) (1) (2) (7) (11)
’20 0 (1) 0 (2) (3)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (4) — — —
’25 (6) (4) (6) (5) (22)
’24 (6) (2) (9) (8) (25)
’23 (4) (6) (5) (10) (25)
’22 (4) (4) (4) (7) (19)
’21 (2) (1) (2) (7) (11)
’20 0 (1) 0 (2) (3)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (2.62) (0.97) — — —
’25 (11.25) (8.75) (7.75) 5.34 (22.40)
’24 (61.75) (49.75) (22.75) (7.50) (120.50)
’23 (56.22) (82.46) (119.94) (86.21) (357.25)
’22 (127.44) (67.47) (63.72) (74.96) (311.09)
’21 (108.70) (78.71) (116.19) (839.58) (1.14k)
’20 (974.51) (224.89) (273.61) 673.14 (802.10)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 521,000,000.00 248,000,000.00 175,000,000.00 4,497.75 864.00 1,215.00 199.13 112.50 27.25 2.88

Analyst estimates 2026–2028

Powerpack
High 1,430,000,000.00 1,049,000,000.00 600,000,000.00 300,000,000.00 22,488.76 3,266.25 1,612.50 521.25 279.50 67.75
People
People Employees 11 9 9 7 9 11 14 17 17 19
Revenue/emp, $m 0.08 0.12 0.11 0.17 0.20 0.04 0.01 0.00 0.23 0.13
Income, $m
Income, $m Revenue 1 1 1 1 2 0 0 — 4 2
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 — 100.00 100.00
EBT (3) (2) (3) (2) (3) (19) (14) (26) (25) (21)
EBT margin, % (394.70) (201.82) (265.79) (201.60) (162.20) (4,817.20) (17,203.80) 0.00 (631.98) (862.35)
Net income (3) (2) (3) (2) (3) (19) (14) (26) (25) (21)
Depreciation 0 0 0 0 0 0 0 0 0 0
Per share, $
Per share, $ Revenue 0.02 0.02 0.00 0.00 492.89 23.65 1.80 0.00 19.10 2.60
Earnings (0.08) (0.03) (149,925,000.00) (294,227.90) (802.10) (1,139.43) (311.09) (357.25) (120.50) (22.40)
Cash flow (0.05) (0.02) 0.00 0.00 (743.41) (686.90) (420.09) (346.27) (119.21) (22.42)
Capex 0.00 0.00 0.00 0.00 (42.38) (2.93) (2.96) (0.67) (0.10) (0.03)
Free cash flow (0.05) (0.02) 0.00 0.00 (785.78) (689.82) (423.06) (346.94) (119.31) (22.44)
Book value 0.01 0.00 0.00 0.00 2,586.19 267.59 587.20 79.28 24.39 3.99
Shares, m 42 69 0 0 0 0 0 0 0 1
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00 0.00
P/S 31,053,854,505.97 37,008,444,940.48 0.00 0.00 2.57 57.40 29.92 — 3.17 0.67
P/B 0.00 0.00 0.00 0.00 0.49 5.07 0.40 — 2.53 1.07
EV/Sales 31,053,854,505.42 37,008,444,940.19 (0.23) (0.21) (2.60) 28.93 (46.26) — 1.91 0.24
EV/FCF (13,119,541,284.17) (23,504,920,550.35) 0.14 0.17 1.63 (0.98) 0.86 — (0.31) (0.07)
Cash, $m
Cash, $m Operating cash flow (2) (2) (2) (1) (3) (11) (19) (25) (25) (21)
Capex — 0 — 0 0 0 0 0 0 0
Free cash flow (2) (2) (2) (1) (3) (11) (19) (25) (25) (22)
Balance, $m
Balance, $m Working capital 0 0 (1) (2) 9 6 24 4 5 3
Total debt — — 0 0 0 — — — — —
Net debt 0 0 0 0 (10) (11) (28) (6) (6) (3)
Shareholders’ equity 0 0 (1) (2) 10 4 27 6 5 4
Returns, %
Returns, % ROA (336.98) (394.44) (452.19) (426.75) (54.46) (167.37) (65.00) (127.82) (286.62) (296.11)
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (1,829.11)
ROE 1,035.68 144.85 98.20 72.93 (98.84) (268.08) (90.57) (160.47) (462.32) (483.78)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2025

Charts ten years each

GeoVax Labs Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
VIVS VivoSim Labs, Inc. $2.8M — (loss-making) — (loss-making) −51.35% (below 0%: shrinking) n/m +17.87% (above 0%: growing) 100.00% (15,327.78%) Compare
AFMDQ Affimed N.V. $2.8M — (loss-making) — (loss-making) −92.02% (below 0%: shrinking) n/m +46.95% (above 0%: growing) 100.00% (9,216.90%) Compare
HCWB HCW Biologics Inc. $2.8M — (loss-making) — (loss-making) +1,954.55% (above 0%: growing) n/m −20.84% (below 0%: shrinking) (69.25%) (2,335.03%) Compare
SLXN Silexion Therapeutics Corp $2.7M — (loss-making) — — n/m −16.63% (below 0%: shrinking) — 0.00% Compare
GOVX GeoVax Labs Inc. $2.6M — (loss-making) — (loss-making) +183.44% (above 0%: growing) n/m +15.81% (above 0%: growing) 100.00% 0.00%
XRTX XORTX Therapeutics Inc. $2.6M — (loss-making) — — n/m −318.40% (below 0%: shrinking) 0.00% 0.00% Compare
EIGRQ Eiger BioPharmaceuticals, Inc. $2.6M — (loss-making) — (loss-making) +41.06% (above 0%: growing) n/m +37.90% (above 0%: growing) 97.34% (331.69%) Compare
BIORQ Biora Therapeutics, Inc. $2.5M — (loss-making) — (loss-making) +1,500.00% (above 0%: growing) n/m +20.72% (above 0%: growing) 100.00% (50,709.38%) Compare
ELAB PMGC Holdings Inc. $2.5M — (loss-making) — +147.70% (above 0%: growing) n/m −44.95% (below 0%: shrinking) 29.52% (292.91%) Compare
Median of peers $2.7M — — +94.38% — +0.62% 97.34% (1,333.36%)

All 614 Biotechnology stocks →

GeoVax Labs Inc. (GOVX) key facts

  • Concern: GeoVax Labs Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 million, down 37.1% from fiscal 2024.
  • GeoVax Labs Inc. (GOVX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, GOVX traded at $0.23, a market capitalization of $2.6 million.
  • Return on equity was −483.8% and debt-to-equity 0.00.
  • Its Altman Z-score is −42.55 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

GeoVax Labs Inc. (GOVX) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/GOVX · Data as of Jun 30, 2025 · For information only; not investment advice. · © 2026 stockrow.com